CC-486 (Oral Azacitidine) in Patients with Myelodysplastic Syndromes with Pretreatment Thrombocytopenia

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and peripheral cytopenias. Approximately 40% of all MDS patients, and up to 80% of patients with higher-risk MDS, experience thrombocytopenia, which is typically defined as platelet count

Source: Leukemia Research - August 3, 2018 Category: Hematology Authors: Guillermo Garcia-Manero, Bart L. Scott, Christopher R. Cogle, Thomas E. Boyd, Suman Kambhampati, Joel Hetzer, Qian Dong, Keshava Kumar, Stacey M. Ukrainskyj, CL Beach, Barry S. Skikne Source Type: research